METTL3 mediates m6A methylation of ADAM17 to Downregulate ACE2–Ang-(1–7) axis and promote progression of hypertension
METTL3-EKD reduces BP and vasoconstriction and prevents cardiovascular remodeling by inhibiting the suppression of ADAM17 in ECs on the ACE2-Ang-(1-7) axis, and then improving Ang II-impaired endothelial function. This study may offer a novel prospective diagnostic or therapeutic strategy for hypertension.
Authors
- Ying Han (ORCID: https://orcid.org/0000-0001-8591-7894)
- Caiyu Li (ORCID: https://orcid.org/0000-0003-1183-2956)
- Pan Yan (ORCID: https://orcid.org/0000-0002-4448-6570)
- Kequan Chen (ORCID: https://orcid.org/0000-0001-8432-7032)
- Ruihua Hu
- Aidong Chen (ORCID: https://orcid.org/0000-0003-2493-402X)
- Jie Bai (ORCID: https://orcid.org/0000-0002-7485-4450)
- Xinrui Zhu (ORCID: https://orcid.org/0000-0002-7197-123X)
- Xuejie Fei
- Lei Zhang (ORCID: https://orcid.org/0000-0003-4498-8236)
- Yu Xu (ORCID: https://orcid.org/0000-0001-9819-1965)
- Xingxing Wang (ORCID: https://orcid.org/0000-0002-9281-2043)
Institutions
- Qingdao University (CN)
- Nanjing University of Chinese Medicine (CN)
- Nanjing Brain Hospital (CN)
- Affiliated Hospital of Qingdao University (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- East China Normal University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal of Advanced Research
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1016/j.jare.2025.08.026
- Citations
- 1
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.81